Nanotechnology Now - Press Release: "AMAG Pharmaceuticals, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference"

Home > Press > AMAG Pharmaceuticals, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at the Canaccord Adams 28th Annual Global Growth Conference on Thursday, August 14 at 3:00 p.m. ET. The conference is being held August 12-14, 2008 in Boston, MA.

AMAG Pharmaceuticals, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference

Cambridge, MA | Posted on July 31st, 2008

A live audio webcast of the presentation will be accessible through the Investors section of the Company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until August 28, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. The Company submitted a New Drug Application (NDA) for marketing approval of ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease patients with the U.S. Food and Drug Administration (FDA) in December 2007. The Company expects FDA action on its NDA in the second half of October 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Carol Miceli
617-498-3361

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: